Dr. Reddy's Laboratories Ltd. said it had launched Decitabine for Injection in 50 mg strength, a therapeutic equivalent generic version of Dacogen (Decitabine for Injection) in the US market on July 11, following the approval by the US FDA of the company's ANDA for Decitabine for Injection.
As per IMS Health data, the Dacogen brand had sales of around $260 million in the US for the twelve months ended July 2013.
The company said the Decitabine for Injection 50 mg would be available as a single dose vial.
At the BSE, Dr. Reddy's Laboratories shares are currently trading at Rs.2,295.95, down 0.21 percent from the previous close.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.